Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many safety-related claims (e.g., C. difficile, kidney TIN, B12 deficiency, hypomagnesemia, bone fracture, severe cutaneous reactions) are generally supported by the provided labeling excerpts, but several items are not supported as stated (notably most “common side effects” and mechanistic/efficacy/comparative claims), and some parts (patents/market exclusivity) are outside the prescribing information scope.
Category Scores
Accurate Statements
Pantoprazole can cause kidney problems (acute tubulointerstitial nephritis has been observed with PPI therapy and may occur at any point during therapy).
Warnings and Precautions 5.2 Acute Tubulointerstitial Nephritis (discontinue and evaluate if suspected).
Pantoprazole is associated with certain gut infections like Clostridium difficile.
Warnings and Precautions 5.3 Clostridium difficile-Associated Diarrhea.
Long-term use of pantoprazole can cause issues with vitamin B12 absorption (cyanocobalamin deficiency with long-term acid suppression over a long period e.g., longer than 3 years).
Warnings and Precautions 5.7 Cyanocobalamin (Vitamin B-12) Deficiency.
Extended use of pantoprazole may be linked to low magnesium levels in the blood.
Warnings and Precautions 5.8 Hypomagnesemia and Mineral Metabolism (reported rarely; for at least three months).
Pantoprazole is associated with a potential increased risk of bone fractures.
Warnings and Precautions 5.4 Bone Fracture.
Pantoprazole can cause severe allergic reactions / severe cutaneous adverse reactions and should be discontinued at first signs or symptoms.
Warnings and Precautions 5.5 Severe Cutaneous Adverse Reactions.
Pantoprazole can cause skin reactions (severe cutaneous adverse reactions have been reported; CLE/SLE reported).
Warnings and Precautions 5.5 Severe Cutaneous Adverse Reactions; 5.6 Cutaneous and Systemic Lupus Erythematosus.
Unsupported Statements
Pantoprazole is associated with common side effects including headache.
Provided label excerpts do not state headache as a common side effect.
Pantoprazole is associated with common side effects including diarrhea.
Provided label excerpts support C. difficile-associated diarrhea risk, but do not state diarrhea as a common side effect.
Pantoprazole is associated with common side effects including nausea.
Provided label excerpts do not list nausea as a common side effect.
Pantoprazole is associated with common side effects including abdominal pain.
Provided label excerpts do not list abdominal pain as a common side effect.
Pantoprazole is associated with common side effects including vomiting.
Provided label excerpts do not list vomiting as a common side effect.
Pantoprazole is associated with common side effects including dizziness.
Provided label excerpts do not list dizziness as a common side effect.
Pantoprazole is associated with common side effects including flatulence.
Provided label excerpts do not list flatulence as a common side effect.
Pantoprazole can cause less common side effects including joint pain.
Provided label excerpts do not list joint pain as an adverse reaction category.
Pantoprazole can cause less common side effects including muscle pain.
Provided label excerpts do not list muscle pain as an adverse reaction category.
Pantoprazole can cause severe allergic reactions.
Label excerpts provided focus on severe cutaneous adverse reactions and lupus; they do not specifically label 'severe allergic reactions' in the way stated.
The increased risk of bone fractures with pantoprazole is particularly noted with high doses or prolonged treatment.
Provided label excerpt states observational studies suggest association with osteoporosis-related fractures; it does not specify 'high doses' in the provided text.
Extended use of pantoprazole, particularly beyond a few months, increases the risk of vitamin B12 deficiency.
Label excerpt specifies long period (e.g., longer than 3 years) for B12 deficiency.
Extended use of pantoprazole, particularly beyond a few months, increases the risk of low magnesium levels.
Label excerpt indicates hypomagnesemia has been reported rarely in patients treated for at least three months; it does not support 'particularly beyond a few months' as stated.
Pantoprazole can be effective for long-term management of gastroesophageal reflux disease (GERD).
Provided label excerpt indicates short-term treatment (up to 8 weeks) for EE healing/symptomatic relief and mentions maintenance of healing of EE (adults) with studies not extending beyond 12 months; it does not support a general statement about long-term GERD management.
Physicians should monitor for potential adverse effects associated with prolonged proton pump inhibitor (PPI) therapy.
The provided label excerpts contain warnings but do not provide a monitoring instruction in this form.
Pantoprazole belongs to the class of drugs called proton pump inhibitors (PPIs).
While consistent with label excerpt, the evaluation is limited to provided text; however the label excerpts explicitly describe it as a PPI—so this is not unsupported. (No penalty applied.)
PPIs work by significantly reducing the amount of acid produced in the stomach.
Provided label excerpt explains binding to (H+,K+)-ATPase results in antisecretory effect, but does not use the phrasing 'significantly reducing the amount of acid produced.' Treated as unsupported as stated.
Pantoprazole provides a stronger and longer-lasting reduction in stomach acid compared with famotidine.
No comparative statement with famotidine is present in provided label excerpts.
H2 blockers work by blocking histamine signals that stimulate acid production.
No label excerpt provided describes H2 blocker mechanism.
H2 blockers lead to a less potent reduction in stomach acid compared to PPIs.
No comparative statement with H2 blockers is present in provided label excerpts.
The increased risk of bone fractures with pantoprazole is particularly noted with high doses or prolonged treatment.
As above, label excerpt does not specify 'high doses' in the provided text.
Pantoprazole treatment duration should be guided by a healthcare professional.
The label provides indicated duration (e.g., up to 8 weeks) and notes safety beyond 8 weeks in pediatrics not established, but does not state this broad instruction in the supplied text.
Pantoprazole can be used for longer periods under medical supervision.
Label excerpt allows an additional 8-week course for adults not healed after 8 weeks; it also mentions maintenance of healing (controlled studies not beyond 12 months). It does not support a general 'longer periods under medical supervision' statement as such.
Physicians should monitor for potential adverse effects associated with prolonged proton pump inhibitor (PPI) therapy.
Warnings are described, but no explicit monitoring directive is shown in the provided excerpts.
Original patents covering the compound and its uses for pantoprazole have expired.
Patent/market exclusivity statements are not present in prescribing information excerpts and are outside the scope of FDA label safety/administration/indication content.
Expiration of original patents for pantoprazole allows introduction of generic versions.
Not supported by provided prescribing information excerpts.
Patents may exist for specific formulations, manufacturing processes, or new therapeutic uses of pantoprazole.
Not supported by provided prescribing information excerpts.
Patents for specific formulations, manufacturing processes, or new therapeutic uses of pantoprazole can affect market exclusivity for those innovations.
Not supported by provided prescribing information excerpts.
Pantoprazole sodium for delayed-release oral suspension is contraindicated in patients receiving rilpivirine-containing products.
This would be supported, but it was not included among the user's claims; only implied via other claims. No direct contraindication claim was listed in the user-provided set.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No specific labeling-supported dosage/administration details (e.g., 40 mg once daily up to 8 weeks; administer ~30 minutes before a meal; only with apple juice/applesauce; do not split/chew/crush) were provided in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While several serious warning-related effects are aligned with the label excerpts (TIN, C. difficile-associated diarrhea, bone fracture association, severe cutaneous reactions, B12 deficiency with long-term therapy, hypomagnesemia), the response also makes multiple 'common' side-effect claims that are not supported by the provided label excerpts, and several duration/long-term management statements are broader than the label indications provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple safety/side-effect claims (especially 'common' side effects, several less-common musculoskeletal/neurologic complaints, and comparative acid-suppression statements) are not supported by the provided label excerpts; some duration/long-term GERD statements are broader than the labeling text provided.
Suggested Improvement
Restrict claims to items explicitly supported in the provided FDA label excerpts (warnings/precautions and stated indicated duration/maintenance limits) and avoid characterizing adverse reactions as 'common' or making comparative efficacy/mechanism statements not present in the labeling.